probucol has been researched along with Focal Segmental Glomerulosclerosis in 5 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study we examined whether lipid-soluble antioxidants, probucol and vitamin E, could inhibit renal injury in rats with chronic puromycin aminonucleoside (PA) nephrosis and dietary hypercholesterolemia by protecting lipoproteins from oxidation." | 3.69 | Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. ( Chung, HK; Jeong, JY; Kim, BC; Kim, YS; Lee, HS; Zhang, YZ, 1997) |
| "Focal segmental glomerulosclerosis is a steroid-resistant glomerular disease characterized by foot process flattening and heavy proteinuria." | 1.30 | Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. ( Binder, CJ; Exner, M; Kerjaschki, D; Weiher, H, 1999) |
| "Probucol treatment significantly reduced the lipid concentration in all major lipoproteins, significantly reduced proteinuria and increased plasma albumin concentration." | 1.28 | Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. ( Hirano, T; Morohoshi, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamasaki, K | 1 |
| Yoshikawa, Y | 1 |
| Naito, H | 1 |
| Hirano, T | 2 |
| Lee, HS | 1 |
| Jeong, JY | 1 |
| Kim, BC | 1 |
| Kim, YS | 1 |
| Zhang, YZ | 1 |
| Chung, HK | 1 |
| Binder, CJ | 1 |
| Weiher, H | 1 |
| Exner, M | 1 |
| Kerjaschki, D | 1 |
| Morohoshi, T | 1 |
5 other studies available for probucol and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Effect of a lipid-lowering agent or a high-cholesterol diet on focal glomerulosclerosis in hyperlipidemic rats.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Glomerulosclerosis, Focal Segmental; Hyperl | 1995 |
Probucol suppresses the development of chronic renal failure in Dahl salt-sensitive rats: an animal model of spontaneous focal and segmental glomerulosclerosis.
Topics: Animals; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Kidney Failure, Chronic; Lipid | 1994 |
Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cholesterol, Dietary; Diet; Glomerulosclerosis, Foc | 1997 |
Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy.
Topics: Aging; Albuminuria; Animals; Disease Models, Animal; Free Radical Scavengers; Glomerulosclerosis, Fo | 1999 |
Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
Topics: Animals; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Male; Nephrotic Syndrome; Probucol; P | 1992 |